InsiderTrades.com logo
9 hidden AI stocks set to thrive in Trump’s new era
From StockEarnings   |   Ad
AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)
Get the Name of These AI Picks Now
Brendan P. Eckelman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Brendan Eckelman Biography and Net Worth

Insider of Inhibrx
Dr. Eckelman co-founded Inhibrx in April 2010 and currently serves as our Chief Scientific Officer and Executive Vice President of Corporate Strategy. From August 2015 to November 2018, he served as our Chief Operating Officer and Vice President of Biotherapeutics. From 2010 until August 2015, Dr. Eckelman served as our Vice President of Scientific Operations. He has served as a member of our board of directors since April 2018.

Dr. Eckelman is the head of our research team, overseeing several key functional areas spanning discovery to therapeutic development. In addition, he has critical responsibilities in corporate strategy and operations. Prior to co-founding Inhibrx, Dr. Eckelman was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation. He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute and received a Ph.D. in Molecular Pathology from the University of California, San Diego (UCSD), School of Medicine. Dr. Eckelman received his B.S. in Molecular Biology and his M.S. in Biology from UCSD.

What is Brendan P. Eckelman's net worth?

The estimated net worth of Brendan P. Eckelman is at least $24.44 million as of May 28th, 2024. Dr. Eckelman owns 1,735,553 shares of Inhibrx stock worth more than $24,436,586 as of November 24th. This net worth estimate does not reflect any other assets that Dr. Eckelman may own. Additionally, Dr. Eckelman receives a salary of $769,250.00 as Insider at Inhibrx. Learn More about Brendan P. Eckelman's net worth.

How old is Brendan P. Eckelman?

Dr. Eckelman is currently 45 years old. There are 3 older executives and no younger executives at Inhibrx. The oldest executive at Inhibrx is Mr. Mark Paul Lappe, Founder, Chairman, President & CEO, who is 57 years old. Learn More on Brendan P. Eckelman's age.

What is Brendan P. Eckelman's salary?

As the Insider of Inhibrx, Inc., Dr. Eckelman earns $769,250.00 per year. The highest earning executive at Inhibrx is Mr. Mark Paul Lappe, Founder, Chairman, President & CEO, who commands a salary of $1,100,000.00 per year. Learn More on Brendan P. Eckelman's salary.

How do I contact Brendan P. Eckelman?

The corporate mailing address for Dr. Eckelman and other Inhibrx executives is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. Inhibrx can also be reached via phone at 858-795-4220 and via email at [email protected]. Learn More on Brendan P. Eckelman's contact information.

Has Brendan P. Eckelman been buying or selling shares of Inhibrx?

Brendan P. Eckelman has not been actively trading shares of Inhibrx during the past quarter. Most recently, Brendan P. Eckelman sold 300,000 shares of the business's stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $34.30, for a transaction totalling $10,290,000.00. Following the completion of the sale, the insider now directly owns 1,735,553 shares of the company's stock, valued at $59,529,467.90. Learn More on Brendan P. Eckelman's trading history.

Who are Inhibrx's active insiders?

Inhibrx's insider roster includes Brendan Eckelman (Insider), Jeffrey Jensen (EVP & Chief Clinical Devel. Officer), and Mark Lappe (Founder). Learn More on Inhibrx's active insiders.

Are insiders buying or selling shares of Inhibrx?

During the last twelve months, Inhibrx insiders bought shares 9 times. They purchased a total of 232,914 shares worth more than $3,618,717.42. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 300,000 shares worth more than $10,290,000.00. The most recent insider tranaction occured on November, 19th when Director Jon Faiz Kayyem bought 69,686 shares worth more than $991,631.78. Insiders at Inhibrx own 22.2% of the company. Learn More about insider trades at Inhibrx.

Information on this page was last updated on 11/19/2024.

Brendan P. Eckelman Insider Trading History at Inhibrx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/28/2024Sell300,000$34.30$10,290,000.001,735,553View SEC Filing Icon  
2/1/2023Sell28,750$24.73$710,987.502,086,803View SEC Filing Icon  
1/3/2023Sell32,895$23.77$781,914.152,122,658View SEC Filing Icon  
12/6/2022Sell40,000$27.22$1,088,800.002,155,553View SEC Filing Icon  
11/1/2022Sell40,000$33.51$1,340,400.002,195,553View SEC Filing Icon  
10/4/2022Sell40,000$27.82$1,112,800.002,235,553View SEC Filing Icon  
8/2/2022Sell24,500$17.70$433,650.002,491,053View SEC Filing Icon  
7/7/2022Sell40,000$17.17$686,800.002,515,553View SEC Filing Icon  
4/5/2022Sell400$25.04$10,016.00View SEC Filing Icon  
3/24/2021Sell17,000$19.02$323,340.00View SEC Filing Icon  
2/16/2021Sell17,000$25.90$440,300.00234,709View SEC Filing Icon  
See Full Table

Brendan P. Eckelman Buying and Selling Activity at Inhibrx

This chart shows Brendan P Eckelman's buying and selling at Inhibrx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inhibrx Company Overview

Inhibrx logo
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $14.08
Low: $13.87
High: $14.28

50 Day Range

MA: $15.61
Low: $13.62
High: $17.49

2 Week Range

Now: $14.08
Low: $10.80
High: $18.95

Volume

68,899 shs

Average Volume

72,791 shs

Market Capitalization

$203.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
9 hidden AI stocks set to thrive in Trump’s new era
From StockEarnings   |   Ad
AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)
Get the Name of These AI Picks Now